-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the last issue of the Lp(a) Masterclass Microclass, we detailed the latest evidence on Lp(a) and cardiovascular disease (CVD) and Lp(a) research areas such as Lp(a) and CVD management latest developmen.
We are honored to invite the chairman of the Severe Cerebrovascular Disease Branch of the Chinese Stroke Association, a member of the Neurological Critical Care Collaborative Group of the Neurology Branch of the Chinese Medical Association, and the Neurology Center of Beijing Tiantan Hospital Affiliated to Capital Medical Universi.
Professor Liu Liping, director of the Neurosurgery Department of Tiantan Cerebrovascular Disease Center, introduced the causal relationship between Lp(a) and stroke in deta.
Summary of key points: ღ The burden of stroke disease is increasi.
The number of stroke patients in China is as high as 13 million, of which about 78% are ischemic stroke, and stroke has become the first cause of death in Chi.
(See video below: 00:00-02:00) Pro-atherosclerotic, pro-thrombotic, and pro-inflammatory mechanisms of ღ Lp(a) may lead to ischemic stro.
(See the video below: 02:01-03:15) ღ Lp(a) is an independent risk factor for ischemic stroke, and elevated Lp(a) levels in patients with ischemic stroke are associated with poor functional outcom.
(See the video below: 03:16-08:36) ღ Pelacarsen is an innovative drug that reduces Lp(a) by inhibiting the synthesis of apo(.
We look forward to the publication of the results of the Phase 3 RCT Horizon stu.
(See the video below: 08:37-13:11) Expert Profile Professor Liu Liping • Director, Professor, Chief Physician, Doctoral Supervisor of Neurology Center, Beijing Tiantan Hospital Affiliated to Capital Medical University, Department of Neurological Intensive Care, Tiantan Cerebrovascular Center Research directions: Neurointensive care and management, Assistant to the President of the Chinese Stroke Society, Chairman of the Severe Cerebrovascular Disease Branch of the Chinese Stroke Society, Member of the Neurocritical Care Collaborative Group of the Neurology Branch of the Chinese Medical Association, and the American Neurological Critical Care Society (NCS) Expert Committee Member, member of the World Stroke Organization (WSO) expert committee; editorial board member of the international journals "Stroke", "Neuroepidemiology", "Europe Stroke Journal", "Journal of Stroke"; He has published books such as "Monitoring and Treatment Manual" and "Cases of Severe Cerebrovascular Diseases"; presided over a number of studies by the Ministry of Science and Technology, the National Natural Science and Technology Commission, and the Municipal Science and Technology Commission, and published more than 100 pape.
Review of past issues ☞ Lipoprotein (a) Master Class .
1 Issue｜A New Vision of Lipid-regulating Therapy, Pr.
Yuan Zuyi discusses the clinical significance of lipoprotein(a) The mechanism (a) Evidence from Chinese population research on CVD ｜Professor Zhu Ye: Treatment of elevated lipoprotein(a) ☞ Small lipoprotein(a) master class .
7｜Professor Chen Zhenyue: The latest progress of lipoprotein(a) and interpretation of relevant guidelines/consensus ☞ Small lipoprotein(a) ) Master Class .
8｜Professor Sun Yihong: Interpretation of expert scientific advice on the relationship between lipoprotein (a) and cardiovascular risk and clinical management (Part 1) ☞ Lipoprotein (a) Master Class .
9｜Professor Guo Yuanlin: Lipoprotein (a) a) Interpretation of expert scientific advice on the relationship with cardiovascular risk and clinical management (Part 2) ☞ Lipoprotein (a) Master Class .
10｜Professor Wu Naqiong: Starting from Lp(a), exploring new strategies for CAVS management ☞ Lipoprotein Lp(a) Master Class .
11｜Professor Liu Meilin: New Progress in Lp(a) Research
We are honored to invite the chairman of the Severe Cerebrovascular Disease Branch of the Chinese Stroke Association, a member of the Neurological Critical Care Collaborative Group of the Neurology Branch of the Chinese Medical Association, and the Neurology Center of Beijing Tiantan Hospital Affiliated to Capital Medical Universi.
Professor Liu Liping, director of the Neurosurgery Department of Tiantan Cerebrovascular Disease Center, introduced the causal relationship between Lp(a) and stroke in deta.
Summary of key points: ღ The burden of stroke disease is increasi.
The number of stroke patients in China is as high as 13 million, of which about 78% are ischemic stroke, and stroke has become the first cause of death in Chi.
(See video below: 00:00-02:00) Pro-atherosclerotic, pro-thrombotic, and pro-inflammatory mechanisms of ღ Lp(a) may lead to ischemic stro.
(See the video below: 02:01-03:15) ღ Lp(a) is an independent risk factor for ischemic stroke, and elevated Lp(a) levels in patients with ischemic stroke are associated with poor functional outcom.
(See the video below: 03:16-08:36) ღ Pelacarsen is an innovative drug that reduces Lp(a) by inhibiting the synthesis of apo(.
We look forward to the publication of the results of the Phase 3 RCT Horizon stu.
(See the video below: 08:37-13:11) Expert Profile Professor Liu Liping • Director, Professor, Chief Physician, Doctoral Supervisor of Neurology Center, Beijing Tiantan Hospital Affiliated to Capital Medical University, Department of Neurological Intensive Care, Tiantan Cerebrovascular Center Research directions: Neurointensive care and management, Assistant to the President of the Chinese Stroke Society, Chairman of the Severe Cerebrovascular Disease Branch of the Chinese Stroke Society, Member of the Neurocritical Care Collaborative Group of the Neurology Branch of the Chinese Medical Association, and the American Neurological Critical Care Society (NCS) Expert Committee Member, member of the World Stroke Organization (WSO) expert committee; editorial board member of the international journals "Stroke", "Neuroepidemiology", "Europe Stroke Journal", "Journal of Stroke"; He has published books such as "Monitoring and Treatment Manual" and "Cases of Severe Cerebrovascular Diseases"; presided over a number of studies by the Ministry of Science and Technology, the National Natural Science and Technology Commission, and the Municipal Science and Technology Commission, and published more than 100 pape.
Review of past issues ☞ Lipoprotein (a) Master Class .
1 Issue｜A New Vision of Lipid-regulating Therapy, Pr.
Yuan Zuyi discusses the clinical significance of lipoprotein(a) The mechanism (a) Evidence from Chinese population research on CVD ｜Professor Zhu Ye: Treatment of elevated lipoprotein(a) ☞ Small lipoprotein(a) master class .
7｜Professor Chen Zhenyue: The latest progress of lipoprotein(a) and interpretation of relevant guidelines/consensus ☞ Small lipoprotein(a) ) Master Class .
8｜Professor Sun Yihong: Interpretation of expert scientific advice on the relationship between lipoprotein (a) and cardiovascular risk and clinical management (Part 1) ☞ Lipoprotein (a) Master Class .
9｜Professor Guo Yuanlin: Lipoprotein (a) a) Interpretation of expert scientific advice on the relationship with cardiovascular risk and clinical management (Part 2) ☞ Lipoprotein (a) Master Class .
10｜Professor Wu Naqiong: Starting from Lp(a), exploring new strategies for CAVS management ☞ Lipoprotein Lp(a) Master Class .
11｜Professor Liu Meilin: New Progress in Lp(a) Research
